News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

Morning Minute: Fannie Mae Accepts Crypto for Mortgages
Decrypt·2026/03/27 15:00
Pound set for steepest monthly decline versus the safe-haven US dollar since October
101 finance·2026/03/27 14:48
Brent: Wider range volatility and concerns over worldwide economic expansion – MUFG
101 finance·2026/03/27 14:36
USD: Funding-driven support in war-driven stress – BBH
101 finance·2026/03/27 14:30
EUR/USD: Mild weakness persists, but 1.14 support remains intact – Scotiabank
101 finance·2026/03/27 14:27

Bitcoin dips under $66K as oil sparks 'unsustainable' US inflation risk
Cointelegraph·2026/03/27 14:27

Umbra opens privacy wallet to the public on Solana, powered by Arcium's encrypted execution engine
The Block·2026/03/27 14:06
AUD/USD Forecast 2026: Main Factors Influencing the Australian Dollar in the Second Quarter
101 finance·2026/03/27 13:42
USD/CAD: Upward momentum aims for the lower 1.39 range – Scotiabank
101 finance·2026/03/27 13:39
Flash
11:54
Ultraman's Wealth Ecosystem Exposed: Helion's Stake Surges to $4.1 Billion, Once Powering $500 Million Investment in OpenAIAccording to Dynamo Beating monitoring, The Wall Street Journal revealed a wealth loop utilized by Sam Altman through an OpenAI commercial contract to inflate personal investment valuations, based on court documents leaked in the Musk v. OpenAI case.Since Altman does not hold OpenAI shares, financial gains rely entirely on personal investments in external startups. The operation of the wealth loop involves OpenAI signing procurement contracts or partnership agreements to boost startup valuations, subsequently attracting OpenAI’s major shareholders (such as Thrive Capital) or partners (such as SoftBank) to invest at a high premium, allowing Altman to directly realize a surge in personal wealth.In June 2026, following OpenAI’s major shareholder Thrive Capital's $15.5 billion valuation investment in the fusion energy company Helion, insiders disclosed that Altman’s personal stake in Helion had more than doubled to at least $4.1 billion. In 2025, Altman had requested OpenAI to invest around $500 million in Helion, causing some employees' unease. OpenAI later rejected this investment; however, in March 2026, the two parties signed a revised new cooperation agreement, and Altman also stepped down as a director of Helion in the same month to avoid conflicts.Furthermore, after chipmaker Cerebras received OpenAI's chip procurement commitment and successfully completed an IPO, Altman's stake in Cerebras had surged by over six times since December 2025.Following a research collaboration between the life extension startup Retro Biosciences and OpenAI, as per evidence disclosed in Elon Musk's lawsuit, Altman's stake in Retro had reached $258 million by December 2025.Currently, at least 10 companies Altman has invested in have related transactions with OpenAI. The United States House Oversight Committee has launched a formal investigation, and several state attorneys general have called for the Securities and Exchange Commission to review Altman.
11:54
Mining company Fortitude, independent from Foundry, will go public through a merger with HeartSciencesForesight News reports, according to The Wall Street Journal, that the independent mining company Fortitude, spun off from Foundry, will be listed on Nasdaq through a merger with HeartSciences. The stock ticker will be "TUDE", and the transaction is expected to be completed in the second half of 2026.Fortitude was established in early 2025 as an independent entity spun off from the proprietary mining division of Foundry, a Digital Currency Group (DCG) mining company. Its business focuses on seeking high-growth, high-return early-stage PoW emerging token opportunities and it is one of the largest miners of Zcash.
11:47
Pharmaceuticals shield exports against tariffs, Italy achieves export growth against the trendItalian Foreign Minister Tajani stated on Tuesday that the pharmaceutical industry is the core driving force behind the country's exports. Despite facing Trump’s tariff rhetoric and two geopolitical conflicts, export performance has remained “remarkable and beyond expectations.”At the conference of the Rome Pharmaceutical Industrial Association, Tajani pointed out that Italy’s economy grew by 3.3% last year, and the preliminary data for early 2026 are also encouraging, with the pharmaceutical sector’s outstanding contribution playing a significant role.He emphasized that exports account for nearly 40% of Italy’s economic output and that the government must support this sector, which has achieved “world-class results,” including by reducing bureaucratic burdens and addressing payment cycle issues.According to data from Italy’s National Institute of Statistics, the country’s pharmaceutical exports to the United States soared by 54.1% last year. Against the backdrop of Trump’s tariff rhetoric, Italy was the only major EU country to achieve export growth to the US.
News
